Dr. Reddy's Laboratories Ltd.

Home
India
Hyderabad
Dr. Reddy's Laboratories Ltd.

We are a global pharmaceutical company committed to providing affordable & innovative medicines. Dr. Reddy’s Laboratories Ltd.

(BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first
Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Dr. Reddy’s does not collect nor does it require you to share any personal data or personal information, towards your access to or participation in the Facebook event organised by it. You are advised to not disclose any personally identifiable or confidential or non-public information on social media; you are personally responsible for any data that you may decide to share or post on any social media including on this page and Dr. Reddy’s owes no duty or obligation or liability to you or to any other person for the same. All participants on this Facebook event are required to behave with courtesy to others and to not post any offensive/objectionable messages or to intrude into any other person’s rights of privacy.

02/12/2025

Our in-house experience design team, Studio 5b, received three awards at the prestigious 15th CII Design Excellence Awards, held during the 25th CII Global Design Summit & Exposition 2025. The summit’s theme, “Design for People, Planet, Purpose and Profitability,” resonates deeply with our approach at Dr. Reddy’s to purposeful design.

Silver – Communication Design for Demystifying Pharma Animated Video Series

Bronze – Experience Design for Dr. Kallam Anji Reddy Memorial Audio Visual Experience

And, Top 50 Designs Made in India for Packaging Design

These recognitions celebrate how design can simplify complex ideas, create immersive experiences, and deliver meaningful impact.

01/12/2025

Today, we honour the progress made in the fight against HIV and reaffirm our commitment to a future free from it.

At Dr. Reddy’s, we are proud to partner with global health organizations—Gilead, CHAI, UNITAID, and WITS RHI—to advance access to Lenacapavir, a twice-yearly HIV prevention injection with potential to transform HIV care. It will be available in 120 low- and middle-income countries post regulatory approval at an affordable access price.

Together, we strive to expand access, challenge stigma, and ensure that innovation reaches those who need it most.

25/11/2025

We’re thrilled to share that the European Commission (EC) has granted marketing authorisation for AVT03, a biosimilar of Prolia® and Xgeva®—both denosumab medicines in different forms.

This approval, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in September, is valid across all EU Member States and the European Economic Area (EEA) countries including Iceland, Liechtenstein, and Norway.

Dr. Reddy’s will offer the biosimilar under the tradenames Acvybra® (60 mg/mL solution in a pre-filled syringe) and Xbonzy® (70 mg/mL solution in a vial). Denosumab works by blocking a protein that causes bone breakdown—helping reduce bone loss in conditions like osteoporosis and preventing bone damage in certain cancers.

With AVT03, our goal is to expand access to high-quality, affordable treatment options for millions affected by osteoporosis and cancer-related bone conditions—improving outcomes and reducing the burden of bone disease across Europe.

Click to read more:https://www.drreddys.com/cms/sites/default/files/2025-11/DRL-finalpressrelease-24thNov2025-Deno.pdf

24/11/2025

Satish Reddy, Chairman, Dr. Reddy’s Laboratories, joined industry leaders at the sixth Pre-Budget Consultation chaired by Hon’ble Union Finance Minister Smt. Nirmala Sitharaman in New Delhi.

He shared his perspective on the importance of risk-based innovation funding to strengthen India’s pharmaceutical ecosystem and accelerate breakthroughs that improve patient access and affordability.

At Dr. Reddy’s, we believe that partnerships between policymakers and industry are vital to building a future-ready healthcare system that serves millions.

Ministry of Finance, Government of India

14/11/2025

Diabetes is a major threat to global health, silently harming the heart, eyes, kidneys,
and more. Yet, over 40% of 589 million people living with diabetes don’t know they
have it. That’s every 9th person!

Watch out for early symptoms: extra thirst, frequent urination, fatigue after meals,
blurry vision and dark patches on the skin.
But sometimes, there are no signs at all, and that’s why screening matters.

Get yourself tested for diabetes if you run the risk.

To know your risk of having diabetes, click here: https://worlddiabetesday.org/type-2-
diabetes-risk-assessment/

(This online diabetes risk assessment is designed by International Diabetes Federation to predict an individual’s risk of developing type 2 diabetes within the next ten years. The test is based on the Finnish Diabetes Risk Score (FINDRISC) developed and designed by Adj. Prof Jaana Lindström and Prof. jaakko tuomilehto from the National Institute for Health and Welfare, Helsinki, Finland.)

05/11/2025

Our Co-chairman and Managing Director, Prasad G V, in conversation with Vishesh Rajaram, Partner of Speciale Invest, at the Speciale Invest 2025 Summit, shared his views on building lasting institutions—where scientific excellence meets scale and purpose.

In a wide-ranging fireside chat, Prasad reflected on Dr. Reddy’s journey from a young research-led company to becoming a global pharmaceutical enterprise. He also discussed how India can continue to lead by combining innovation and entrepreneurship—while also being responsible.

27/10/2025

We welcome back Srinivas Mallavarapu to the Dr. Reddy’s family as Head, Global Portfolio and Head, Business Development, North America.

With over 25 years of global experience, Srini brings deep expertise in portfolio strategy and business development. His return marks a renewed commitment to purpose-driven leadership, patient-centric innovation, and strategic growth across generics, biosimilars, and OTC segments.

Here’s to shaping a healthier tomorrow, because Good Health Can’t Wait.

25/10/2025

We’re proud to share that Dr. Reddy’s Canada has been honoured with the D.W. Bole Distinction Award by McKesson Canada, a recognition reserved for the top-performing pharmaceutical partner across the country.

This award is a resounding acknowledgment of what we stand for: operational excellence, innovation, and collaboration that truly makes a difference to patient care.

Grateful to McKesson Canada for this honour, and kudos to the Canada team for living our purpose every day.

Sai Swaroop Mishra Rob Herrington Milan Kalawadia

24/10/2025

Today we announced our Q2 FY'26 financial results.

For more details click here:https://www.drreddys.com/cms/sites/default/files/2025-10/EarningsRelease_Q2FY26_24102025_Final.pdf

16/10/2025

11 days to go for CPHI Frankfurt 2025!

Our teams from Dr. Reddy’s—representing Active Pharmaceutical Ingredients, Formulations, Biologics, Aurigene Pharmaceutical Services Limited (CRDMO), Aurigene Oncology Limited (Oncology drug discovery), Global Manufacturing Organisation (GMO), and Integrated Product Development Organisation (IPDO)—will be present and ready to discuss how we can sustainably increase access to affordable and innovative medicines together.

You can meet us at Hall 9.1, Stand B48 from October 28–30 at Messe Frankfurt.

We look forward to seeing you there!

11/10/2025

We just wrapped up the India Market Edition of Impact Day—and what an inspiring experience it was! Held at our Leadership Academy in Bachupally, this edition brought colleagues closer to the heart of our purpose. Impact Day is designed to deepen our understanding of therapy areas, the science behind our products, and the lived experiences of patients.

This edition focused on the complexities and nuances of Dr. Reddy’s India Market, featuring insights from our leadership and medical experts. Satish Reddy, our Chairman, opened the day by reflecting on the early days of our journey in India—highlighting our purpose, policies, and the contributions that shaped our growth. M.V. Ramana, CEO – Branded Markets (India & EM), spoke about our API development and efforts to expand access through affordability. Manish Bajaj, Cluster Head – Launch Incubation, shared our journey from market entry to crossing the ₹5,000 crore mark, ranking among the top 10 in revenue and top 3 in quality perception in India.

Key highlights included a dialogue on ‘Exploring Indian Patient Nuances’ led by Dr. Bhavesh Kotak, Dr. Snehal Sameer Muchhala, and V.K. Ashok, who discussed patient journeys and our patient care programs. Ajay Naigaonkar reflected on the evolution of our delivery ecosystem—from its early days to the complex network it is today. Brand speaker sessions were delivered by Yogesh Birari, Firoz Khan, Ritesh Jain, and Deepak Manot. They shared insights on building big brands in India, including the Venusia skincare range, Consumer Health and Rx products, and patient success stories. Sandeep Khandelwal, Head – GG India, shared perspectives on decoding India Market opportunities, touching upon patient-centric solutions, evolving standards of care, policy shaping, regulatory reforms, and more.

Over 550 colleagues participated and attended the open house, which featured experiential booths offering immersive field force and gamified experiences, along with brand journey showcases. Impact Day reflects our commitment to understanding our work from the inside out—and to delivering agile, patient-centric solutions.

Address

Dr. Reddy's Laboratories Limited (Corporate Office), Door No 8-2-337, Road No 3, Banjara Hills
Hyderabad
500034

Website

https://www.drreddys.com/

Alerts

Be the first to know and let us send you an email when Dr. Reddy's Laboratories Ltd. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Hyderabad?